Suramin in Treating Patients With Recurrent Primary Brain Tumors

Phase 2

Completed

• Conditions: Brain and Central Nervous System Tumors

• Registration Number: NCT00002639
• Lead Sponsor: Emory University

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients with recurrent primary brain tumors following radiation therapy.

Detailed Description

OBJECTIVES: I. Estimate the efficacy of suramin in patients with recurrent primary brain tumors as measured by radiographic response, time to progression, and survival. II. Assess the toxic effects of suramin in this patient population.

OUTLINE: Single-Agent Chemotherapy. Suramin, SUR, NSC-34936.

PROJECTED ACCRUAL: If at least 1 of the first 14 patients experiences at least a partial response, a total of 25 patients will be entered over approximately 30 months.

Study Timeline

• Study Start: 1995-07
• Study First Submitted: 1999-11-01
• Status Verified: 2001-02
• Study Completion: 2004-05
• Study First Submitted QC: 2004-05-25
• Study First Posted: 2004-05-26
• Last Update Submitted: 2013-06-20
• Last Update Posted: 2013-06-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Department of Neurosurgery - Emory; 🇺🇸 Atlanta, Georgia, United States